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AIM OF STUDY 
The objectives of the study are: 
1) To study the prevalence of low Ankle brachial pressure index in 
people with coronary arterial disease in patients of Coimbatore Medical 
College when compared with general population of same locality. 
2) To find out whether ABPI is a significant individual risk factor for 
coronary arterial disease. 
 
 
  
 
 
 
 
  
 
 
 
 
 
Introduction
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INTRODUCTION 
American heart association prevention conference V described Ankle 
brachial pressure index (ABPI) test as a “simple, inexpensive, noninvasive 
measure” of peripheral arterial disease and stated that an abnormal ABI 
“provides incremental coronary and all cardiovascular disease risk 
assessment information”. Measurement of ABPI has been recommended to 
improve cardiovascular risk assessment in individuals in individuals at 
“intermediate or higher risk of coronary arterial disease (CAD) on basis of 
traditional risk factor assessment” (1).although several studies have 
demonstrated that ABPI <0.9 predicts future CAD mortality, there is little 
data regarding the utility of ABPI as a screening test in individuals for whom 
physicians actually order non invasive test for cardiovascular risk prediction. 
So, this study was performed to find the prevalence of low ABPI 
(<0.9) in clinical cases of coronary arterial disease patients and compare it 
with those who were free of disease clinically in the same group of 
population.   
Low ABPI reflects peripheral arterial disease of lower limbs, and is 
used as a tool in treating an ischaemic limb, due to any cause, most common 
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of which is atherosclerosis. Epidemiological studies have demonstrated that 
subclinical cardiovascular disease in one vascular bed is associated with the 
presence of clinical disease in another bed, as well as with subsequent 
cardiovascular and total mortality. As, coronary arterial disease also shares a 
common etiology of atherosclerosis with peripheral arterial disease, ABPI 
can be used to predict its risk. Individuals with peripheral arterial disease of 
the lower extremities  are among the highest-risk vascular patients. 
Therefore, presence of peripheral arterial disease is an indicator of 
widespread atherosclerosis in other vascular territories such as the coronary, 
carotid, and cerebrovascular arteries (2 , a-d) . 
  
 
 
 
 
 
 
 
Review of literature
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REVIEW OF LITERATURE 
   
 Clinical manifestation of peripheral arterial disease confirmed 
by reduced ankle-brachial pressure index (ABPI) ranges from the common 
asymptomatic disease, to the less prevalent intermittent claudication, to the 
relatively rare critical limb ischemia with rest pain, ulceration or gangrene . 
Even if peripheral arterial disease does not cause typical claudication, it 
reduces walking speed and walking endurance (3). Regardless of the clinical 
symptoms, reduced ABPI is a sign of hemodynamic disturbance in the 
arterial supply of the lower limbs, which is strongly associated with 
atherosclerosis in the coronary and carotid territories (4). Thus, peripheral 
arterial disease is associated with increased mortality due to myocardial 
infarction and ischemic stroke. Several studies described 2-3-fold greater 
mortality in patients with peripheral arterial disease in comparison with age-
matched controls with normal ABPI; patients with peripheral arterial disease 
had a 5-year mortality of about 30% (5-10). Increasing severity of peripheral 
arterial disease, expressed as diminishing ABPI, progressively reduces 
survival (7-10). 
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Most previously studied cohorts were either patients referred for non-
invasive vascular testing (7) or patients with known risk factors such as 
hypertension (9) or hyperlipidemia (5). .(metlika study) 
 
  ANKLE BRACHIAL PRESSURE INDEX  
The Ankle Brachial Pressure Index (ABPI) is the ratio of the blood 
pressure in the lower legs to the blood pressure in the arms. Compared to the 
arm, lower blood pressure in the leg is a symptom of blocked arteries 
(peripheral vascular disease). The ABPI is calculated by dividing the 
systolic blood pressure in the arteries at the ankle and foot by the higher of 
the two systolic blood pressures in the arm. 
 
 
 
 
 
 
 MEASUREMENT OF ABPI: 
 Figure 1: EQUIPMENTS USED. 
 
 
  Figure 2: Procedure 
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 Figure 3: Measurement in arm. 
 
 
 
 Figure 4: Measurement in leg. 
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A Doppler ultrasound blood flow detector, commonly called Doppler Wand 
or Doppler probe, is used to register the peripheral pulse while a 
sphygmomanometer (blood pressure cuff) is inflated over the artery until the 
pulse ceases, proximal to the Doppler probe. The cuff is slowly deflated, and 
the corresponding sphygmomanometer pressure at the instant the pulse 
returns provides the systolic blood pressure reading, for the given artery. 
The higher of the left and right arm brachial artery pressure is generally used 
in the assessment. The pressures in each foot's artery and dorsalis pedis 
artery are measured with the higher of the two values used as the ABPI for 
that leg. [12] 
ABPI = P Leg / P Arm
Where PLeg is the systolic blood pressure of dorsalis pedis or 
posterior tibial arteries and PArm is the highest of the left and right arm 
brachial artery pulse pressure 
The ABPI test is a popular tool for the non-invasive assessment of PVD. 
Studies have shown the sensitivity of ABPI is 90% with a corresponding 
98% specificity for detecting  hemodynamically significant 
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(Serious) stenosis >50% in major leg arteries, defined by angiogram[13].
Palpation of peripheral pulses should be a routine component of all 
physical examination and should include assessment of the femoral, 
popliteal, and pedal vessels. It should be noted that pulse assessment is a 
learned skill and has a high degree of interobserver variability, with high 
false-positive and false-negative rates. The dorsalis pedis pulse is 
reported to be absent in 8.1% of healthy individuals, and the posterior 
tibial pulse is absent in 2.0%. Nevertheless, the absence of both pedal 
pulses, when assessed by a person experienced in this technique, 
strongly suggests the presence of vascular disease. 
  In contrast to the variability of pulse assessment and the often 
nonspecific nature of information obtained via history and other 
components of the physical exam, the ABI is a reproducible and 
reasonably accurate, noninvasive measurement for the detection of PAD 
and the determination of disease severity . 
However, ABPI has known issues:- 
 ABPI is known to be unreliable on patients with 
arterial calcification (Hardening of the arteries) which results in less 
or incompressible arteries[14], as the stiff arteries produce 
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falsely elevated ankle pressure, giving false negatives[15]). This is 
often found in patients with diabetesmelitus[16] (41% of PAD patients 
have diabetes[17]), renal failure or heavy smokers. ABPI values >1.3 
should be investigated further regardless. 
 Performing ABPI is time consuming[18]. 
 Resting ABPI is insensitive to mild PAD[19]. Treadmill tests (6 
minute) are sometimes used to increase ABPI sensitivity[20], but this 
is unsuitable for patients who are obese or have co-morbidities such 
as Aortic aneurysm, and increases assessment duration. 
 Lack of protocol standardisation[21], which reduces intra-observer 
reliability[22]. 
 Skilled Operators are required for consistent, accurate results[23]. 
Interpretation of results
In a normal subject the pressure at the ankle pulses is slightly higher 
than at the elbow (there is reflection of the pulse pressure from the 
vascular bed of the feet, whereas at the elbow the artery continues on 
some distance to the wrist). The ABPI is the ratio of the highest ankle to 
brachial artery pressure and an ABPI of greater than 0.9 is considered 
normal ,free from significant PAD. 
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However, an ABPI value greater than 1.3 is considered abnormal, and 
suggests calcification of the walls of the arteries and incompressible 
vessels, reflecting severe peripheral vascular disease. 
Provided that there are no other significant conditions affecting the 
arteries of the leg, the following ABPI ratios can be used to predict the 
severity of PAD as well as assess the nature and best management of 
various types of leg ulcers:[12]
         TABLE-1 
ABPI value Interpretation 
above 1.3 Abnormal (Vessel hardening from PAD) 
1.0 - 1.3 Normal range 
0.9 - 1.0 Acceptable 
0.8 - 0.9 Some arterial disease 
0.5 - 0.8 Moderate arterial disease 
under 0.5 Severe arterial disease 
Lower limb ischaemia, resulting from atherosclerosis, is a common finding 
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in middle-aged and elderly people. Its prevalence is significantly higher in 
diabetic patients than in non-diabetic patients. Around5% of adults who 
were older than 40 years of age had PAD, and two-thirds had no symptoms. 
The prevalence of the disease is 1.8 times among diabetic patients than non-
diabetic patients, thus early detection of the disease in people at risk would 
help in early management. Screening of PAD of the lower limb was 
performed utilising different ways, such as history suggestive of lower limb 
claudication, palpation of foot pulses, and measuring ABPI by Doppler 
US.(6,7,10) Relying on the history of intermittent claudication alone to make 
a diagnosis of PAD, or even as a screening method before further detailed 
examination, may cause many cases to be missed because of common co 
morbid problems that may cause leg pain.(11,12) The same applies for 
palpating foot pulses, as 8% of the dorsalis pedis and 2% of the posterior 
tibial arteries are not palpable in healthy individuals, but detectable by 
Doppler US. ABI is an easy and objective way of evaluating lower limb 
blood flow. In fact, it was also shown that the PAD screening score using a 
hand-held Doppler US provides the greatest diagnostic accuracy. (14, 15)  
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Predictor of atherosclerosis mortality
Though, ABPI is mainly used in detecting and grading the severity of 
stenosis of vessel in peripheral arterial disease patients, Studies in 2006 
suggest that an abnormal ABPI may be an independent predictor of 
mortality, as it reflects the burden of atherosclerosis.[24] [25]  this is based 
on the fact that, a systemic process like atherosclerosis, which is the 
most important cause of coronary events, also involves the peripheral 
vessels. This can be made use of , in predicting the future coronary 
events early and halt the actual occurrence of a major catastrophe bye 
appropriate intervention, either pharmacological or life style 
modifications. 
A brief overview of atherosclerosis and coronary arterial disease may be 
important in understanding the significance of ABPI in detecting the 
occlusive process. 
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ATHEROSCLEROSIS:
     Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic 
inflammatory response in the walls of arteries, in large part due to the 
accumulation of macrophage white blood cells and promoted by low density 
(especially small particle) lipoproteins (plasma proteins that 
carry cholesterol and triglycerides) without adequate removal of fats and 
cholesterol from the macrophages by functional high density 
lipoproteins(HDL), (see apoA-1 Milano). It is commonly referred to as a 
"hardening" or "furring" of the arteries. It is caused by the formation of 
multiple plaques within the arteries.[26]
The atheromatous plaque is divided into three distinct components: 
1. The atheroma ("lump of porridge", from Athera, porridge in Greek,), 
which is the nodular accumulation of a soft, flaky, yellowish material 
at the center of large plaques, composed of macrophages nearest 
the lumen of the artery 
2. Underlying areas of cholesterol crystals 
3. Calcification at the outer base of older/more advanced lesions. 
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The following terms are similar, yet distinct, in both spelling and 
meaning, and can be easily confused: arteriosclerosis, arteriolosclerosis, and 
atherosclerosis. Arteriosclerosis is a general term describing any hardening 
(and loss of elasticity) of medium or large arteries (from the Greek Arterio, 
meaning artery, and sclerosis, meaning hardening); arteriolosclerosis is any 
hardening (and loss of elasticity) of arterioles (small 
arteries); atherosclerosis is a hardening of an artery specifically due to an 
atheromatous plaque. Therefore, atherosclerosis is a form of arteriosclerosis. 
Atherosclerosis, though typically asymptomatic for decades, 
eventually produces two main problems: First, the atheromatous plaques, 
though long compensated for by artery enlargement (see IMT), eventually 
lead to plaque ruptures and clots inside the artery lumen over the ruptures. 
The clots heal and usually shrink but leave behind stenosis (narrowing) of 
the artery (both locally and in smaller downstream branches), or worse, 
complete closure, and, therefore, an insufficient blood supply to the tissues 
and organ it feeds. Second, if the compensating artery enlargement process 
is excessive, then a net aneurysm results. 
These complications of advanced atherosclerosis are chronic, slowly 
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progressive and cumulative. Most commonly, soft plaque suddenly ruptures 
(see vulnerable plaque), causing the formation of a thrombus that will 
rapidly slow or stop blood flow, leading to death of the tissues fed by the 
artery in approximately 5 minutes. This catastrophic event is called 
an infarction. One of the most common recognized scenarios is coronary 
thrombosis of a coronary artery, causing myocardial infarction (a heart 
attack). Even worse is the same process in arteries to the brain, commonly 
called stroke. Another common scenario in very advanced disease 
is claudication from insufficient blood supply to the legs, typically due to a 
combination of both stenosis and aneurysmal segments narrowed with clots. 
Since atherosclerosis is a body-wide process, similar events occur also in the 
arteries to the brain, intestines, kidneys, legs, etc. 
Causes 
Atherosclerosis develops from low-density lipoprotein molecules 
(LDL) becoming oxidized (ldl-ox) by free radicals, particularly oxygen free 
radicals (ROS). Blood in arteries contains plenty of oxygen and is where 
atherosclerosis develops. Blood in veins contains little oxygen where 
atherosclerosis rarely develops. When oxidized LDL comes in contact with 
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an artery wall, a series of reactions occurs to repair the damage to the artery 
wall caused by oxidized LDL. The LDL molecule is globular shaped with a 
hollow core for carrying cholesterol throughout the body for making brain 
tissue, vitamin D, etc. Cholesterol does not dissolve in water. Blood is 70% 
water. The only way cholesterol can move in the bloodstream is to be carried 
by LDL. 
The body's immune system responds to the damage to the artery wall 
caused by oxidized LDL by sending specialized white blood cells 
(macrophages and T-lymphocytes) to absorb the oxidized-LDL. 
Unfortunately, these white blood cells are not able to process the oxidized-
LDL, and ultimately grow then rupture, depositing a greater amount of 
oxidized cholesterol into the artery wall. This triggers more white blood 
cells, continuing the cycle. 
Eventually, the artery becomes inflamed. The cholesterol plaque 
causes the muscle cells to enlarge and form a hard cover over the affected 
area. This hard cover is what causes a narrowing of the artery, reduces the 
blood flow and increases blood pressure. 
Some researchers believe that atherosclerosis may be caused by an 
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infection of the vascular smooth muscle cells. Chickens, for example, 
develop atherosclerosis when infected with the Marek's disease herpes 
virus.[27] Herpes virus infection of arterial smooth muscle cells has been 
shown to cause cholesteryl ester (CE) accumulation.[28] Cholesteryl 
ester accumulation is associated with atherosclerosis. 
Symptoms 
Atherosclerosis typically begins in early adolescence, and is usually 
found in most major arteries, yet is asymptomatic and not detected by most 
diagnostic methods during life. The stage immediately prior to actual 
atherosclerosis is known as sub clinical atherosclerosis. The majority of the 
process leading to sub clinical atherosclerosis can happen without our 
knowing it, especially given the large variety of risk factors.[29] Autopsies of 
healthy young men who died during the Korean and Vietnam Wars showed 
evidence of the disease.[30][31] It most commonly becomes seriously 
symptomatic when interfering with the coronary circulation supplying 
the heart or cerebral circulation supplying the brain, and is considered the 
most important underlying cause of strokes, heart attacks, various heart 
diseases including congestive heart failure, and most cardiovascular 
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diseases, in general. Atheroma in arm, or more often in leg arteries, which 
produces decreased blood flow, is called peripheral artery occlusive 
disease (PAOD). 
Most artery flow disrupting events occur at locations with less than 
50% lumen narrowing (~20% stenosis is average). 
Atherogenesis 
Atherogenesis is the developmental process of atheromatous plaques. 
It is characterized by a remodeling of arteries involving the concomitant 
accumulation of fatty substances called plaques. One recent theory suggests 
that, for unknown reasons, leukocytes, such as monocytes or basophils, 
begin to attack the endothelium of the artery lumen in cardiac muscle. The 
ensuing inflammation leads to formation of atheromatous plaques in the 
arterial tunica intima, a region of the vessel wall located between 
the endothelium and the tunica media. The bulk of these lesions is made of 
excess fat, collagen, and elastin. At first, as the plaques grow, only wall 
thickening occurs without any narrowing, stenosis of the artery opening, 
called the lumen; stenosis is a late event, which may never occur and is often 
the result of repeated plaque rupture and healing responses, not just the 
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atherosclerosis process by itself. 
Cholesterol is delivered into the vessel wall by cholesterol-
containing low-density lipoprotein (LDL) particles. To attract and stimulate 
macrophages, the cholesterol must be released from the LDL particles and 
oxidized, a key step in the ongoing inflammatory process. The process is 
worsened if there is insufficient high-density lipoprotein (HDL), the 
lipoprotein particle that removes cholesterol from tissues and carries it back 
to the liver. 
The foam cells and platelets encourage the migration and proliferation 
of smooth muscle cells, which in turn ingest lipids, become replaced by 
collagen and transform into foam cells themselves. A protective fibrous cap 
normally forms between the fatty deposits and the artery lining (the intima). 
These capped fatty deposits (now called 'atheromas') produce 
enzymes that cause the artery to enlarge over time. As long as the artery 
enlarges sufficiently to compensate for the extra thickness of the atheroma, 
then no narrowing ("stenosis") of the opening ("lumen") occurs. The artery 
becomes expanded with an egg-shaped cross-section, still with a circular 
opening. If the enlargement is beyond proportion to the atheroma thickness, 
then an aneurysm is created. [32]
Visible features 
 
Severe atherosclerosis of the aorta. Autopsy specimen. 
Although arteries are not typically studied microscopically, two 
plaque types can be distinguished [26]: 
1. The fibro-lipid (fibro-fatty) plaque 
2. The fibrous plaque (under the intima)  
The calcification deposits, after they have become sufficiently 
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advanced, are partially visible on coronary artery computed 
tomography or electron beam tomography (EBT) as rings of increased 
radiographic density, forming halos around the outer edges of the 
atheromatous plaques, within the artery wall. On CT, >130 units on 
the Hounsfield scale {some argue for 90 units) has been the radiographic 
density usually accepted as clearly representing tissue calcification within 
arteries. These deposits demonstrate unequivocal evidence of the disease, 
relatively advanced, even though the lumen of the artery is often still normal 
by angiographic or intravascular ultrasound. 
Rupture and stenosis 
Although the disease process tends to be slowly progressive over 
decades, it usually remains asymptomatic until an atheroma obstructs the 
bloodstream in the artery. This is typically by rupture of an atheroma, 
clotting and fibrous organization of the clot within the lumen, covering the 
rupture but also producing stenosis, or over time and after repeated ruptures, 
resulting in a persistent, usually localized stenosis. Stenoses can be slowly 
progressive, whereas plaque rupture is a sudden event that occurs 
specifically in atheromas with thinner/weaker fibrous caps that have become 
"unstable." 
If the fibrous cap separating a soft atheroma from the bloodstream 
within the artery ruptures, tissue fragments are exposed and released, and 
blood enters the atheroma within the wall and sometimes results in a sudden 
expansion of the atheroma size. Tissue fragments are very clot-promoting, 
containing collagen and tissue factor; they activate platelets and activate 
the system of coagulation. The result is the formation of athrombus (blood 
clot) overlying the atheroma, which obstructs blood flow acutely. With the 
obstruction of blood flow, downstream tissues are starved of oxygen and 
nutrients. If this is the myocardium (heart muscle), angina (cardiac chest 
pain) or myocardial infarction (heart attack) develops. 
 
Microphotography of arterial wall with calcified (violet colour) atherosclerotic plaque 
(haematoxillin & eosin stain) 
Areas of severe narrowing, stenosis, detectable by angiography, and to 
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a lesser extent "stress testing" e.g. ABPI, have long been the focus of human 
diagnostic techniques for cardiovascular disease, in general. However, these 
methods focus on detecting only severe narrowing, not the underlying 
atherosclerosis disease.  
Greater than 75% lumen stenosis used to be considered by 
cardiologists as the hallmark of clinically significant disease because it is 
typically only at this severity of narrowing of the larger heart arteries that 
recurring episodes of angina and detectable abnormalities by stress testing 
methods are seen. However, clinical trials have shown that only about 14% 
of clinically-debilitating events occur at locations with this, or greater 
severity of narrowing. The majority of events occur due to atheroma plaque 
rupture at areas without narrowing sufficient enough to produce any 
angina or stress test abnormalities. Thus, since the later-1990s, greater 
attention is being focused on the "vulnerable plaque."[34]
Though any artery in the body can be involved, usually only 
severe narrowing or obstructions of some arteries, those that supply more 
critically-important organs are recognized. Obstruction of arteries supplying 
the heart muscle results in a heart attack. Obstruction of arteries supplying 
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the brain results in a stroke. These events are life-changing, and often result 
in irreversible loss of function because lost heart muscle and brain cells do 
not grow back to any significant extent, typically less than 2%. 
Over the last couple of decades, methods other than angiography and 
stress-testing, like ABPI etc,  have been increasingly developed as ways to 
better detect atherosclerotic disease before it becomes symptomatic. These 
have included both (a) anatomic detection methods and (b) physiologic 
measurement methods. 
Examples of anatomic methods include: (1) coronary calcium scoring 
by CT, (2) carotid IMT (intimal media thickness) measurement by 
ultrasound, and (3) ABPI. 
Examples of physiologic methods include: (1) lipoprotein subclass 
analysis, (2) HbA1c, (3) hs-CRP, and (4) homocysteine. 
The example of the metabolic syndrome combines both anatomic 
(abdominal girth) and physiologic (blood pressure, elevated blood glucose) 
methods. 
Advantages of these two approaches: The anatomic methods directly 
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measure some aspect of the actual atherosclerotic disease process itself, thus 
offer potential for earlier detection, including before symptoms start, disease 
staging and tracking of disease progression. The physiologic methods are 
often less expensive and safer and changing them for the better may slow 
disease progression, in some cases with marked improvement. 
Disadvantages of these two approaches: The anatomic methods are 
generally more expensive and several are invasive. The physiologic methods 
do not quantify the current state of the disease or directly track progression. 
For both, clinicians and third party payers have been slow to accept the 
usefulness of these newer approaches. 
Physiologic factors that increase risk 
Various anatomic, physiological & behavioral risk factors for 
atherosclerosis are known.[35] These can be divided into various categories: 
congenital vs acquired, modifiable or not, classical or non-classical. The 
points labelled '+' in the following list form the core components of 
"metabolic syndrome". 
Factors add to each other multiplicatively, with two factors increasing 
the risk of atherosclerosis fourfold.[36] Hyperlipidemia, 
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hypertension and cigarette smoking together increases the risk seven 
times.[36]
Modifiable 
 Having Diabetes[36] or Impaired glucose tolerance (IGT) + 
 Dyslipoproteinemia[36] (unhealthy patterns of serum proteins carrying 
fats & cholesterol): + 
 High serum concentration of low-density lipoprotein (LDL, 
"bad if elevated concentrations and small"), and / or very low 
density lipoprotein(VLDL) particles, i.e., "lipoprotein subclass 
analysis" 
 Low serum concentration of functioning high density 
lipoprotein (HDL "protective if large and high enough" 
particles), i.e., "lipoprotein subclass analysis" 
 An LDL:HDL ratio greater than 3:1 
 Tobacco smoking, increases risk by 200% after several pack years [36] 
 Having high blood pressure +, on its own increasing risk by 60%[36] 
 Elevated serum C-reactive protein concentrations[36] 
Nonmodifiable 
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 Advanced age [36] 
 Male sex[36] 
 Having close relatives who have had some complication of 
atherosclerosis (e.g. coronary heart disease or stroke)[36] 
 Genetic abnormalities,[11] e.g. familial hypercholesterolemia 
Lesser or uncertain 
The following factors are of relatively lesser importance, are uncertain 
or nonquantitated: 
 Being obese] (in particular central obesity, also referred to 
as abdominal or male-type obesity) + 
 A sedentary lifestyle[36] 
 Postmenopausal estrogen deficiency[36] 
 High carbohydrate intake[36] 
 Intake of trans fat[36] 
 Elevated serum levels of triglycerides + 
 Elevated serum levels of homocysteine 
 Elevated serum levels of uric acid (also responsible for gout) 
 Elevated serum fibrinogen concentrations 
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 Elevated serum lipoprotein(a) concentrations [36] 
 Chronic systemic inflammation as reflected by upper normal WBC 
concentrations, elevated hs-CRP and many other blood chemistry 
markers, most only research level at present, not clinically done.[37] 
 Stress[36] or symptoms of clinical depression 
 Hyperthyroidism (an over-active thyroid) 
 Elevated serum insulin levels + [38] 
 Chlamydia pneumoniae infection[36] 
Dietary risk factors 
The relation between dietary fat and atherosclerosis is a contentious 
field. The USDA, in its food pyramid, promotes a low-fat diet, based largely 
on its view that fat in the diet is atherogenic. 
The role of dietary oxidized fats / lipid peroxidation (rancid fats) in 
humans is not clear. Laboratory animals fed rancid fats develop 
atherosclerosis. Rats fed DHA-containing oils experienced marked 
disruptions to their antioxidant systems, as well as accumulated significant 
amounts of peroxide in their blood, livers and kidneys.[41] Rancid fats and 
oils taste very bad even in small amounts; people avoid eating them.[44] It is 
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very difficult to measure or estimate the actual human consumption of these 
substances.[45] In addition, the majority of oils consumed in the United States 
are refined, bleached, deodorized and degummed by manufacturers. The 
resultant oils are colorless, odorless, tasteless and have a longer shelf life 
than their unrefined counterparts.[46]This extensive processing serves to 
make peroxidated, rancid oils much more elusive to detection via the various 
human senses than the unprocessed alternatives. 
The French paradox is the observation that despite having a diet 
similar to those United States in terms of fat intake, rates of heart disease are 
lower in France. There is evidence to suggest the French paradox is due to 
underestimation of the rates of heart disease in France.[47]
Prognosis 
Lipoprotein imbalances, upper normal and especially elevated blood 
sugar, i.e., diabetes and high blood pressure are risk factors for 
atherosclerosis; homocysteine, stopping smoking, 
taking anticoagulants (anti-clotting agents), which target clotting factors, 
taking omega-3 oils from fatty fish or plant oils such as flax or canola oils, 
exercising and losing weight are the usual focus of treatments that have 
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proven to be helpful in clinical trials. The target serum cholesterol level is 
ideally equal or less than 4mmol/L (160 mg/dL), and triglycerides equal or 
less than 2mmol/L (180 mg/dL).Diabetes is alone atherogenic. 
Treatment 
If atherosclerosis leads to symptoms, some symptoms such as angina 
pectoris can be treated. Non-pharmaceutical means are usually the first 
method of treatment, such as cessation of smoking and practicing regular 
exercise. If these methods do not work, medicines are usually the next step 
in treating cardiovascular diseases, and, with improvements, have 
increasingly become the most effective method over the long term. 
However, medicines are criticized for their expense, patented control and 
occasional undesired effects. 
Statins 
Statins have shown ~25% comparative mortality reduction in clinical 
trials, although one study design, ALLHAT, [48] was less strongly favorable. 
The newest statin, rosuvastatin, has been the first to demonstrate 
regression of atherosclerotic plaque within the coronary 
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arteries by IVUS(intravascular ultrasound evaluation).33]  
The success of statin drugs in clinical trials is based on some reductions in 
mortality rates, however by trial design biased toward men and middle-age, 
the data is as, as yet, less strongly clear for women and people over the age 
of 70[49]. The ASTEROID trial has been the first to show actual disease 
volume regression[33] (see page 8 of the paper, which shows cross-sectional 
areas of the total heart artery wall at start and 2 years of rosuvastatin 40 
mg/day treatment); however, its design was not able to "prove" the mortality 
reduction issue since it did not include a placebo group, the individuals 
offered treatment within the trial had advanced disease and promoting a 
comparison placebo arm was judged to be unethical. 
Primary and Secondary Prevention—Studies 
Combinations of statins, niacin, intestinal cholesterol absorption-
inhibiting supplements (ezetimibe and others, and to a much lesser 
extentfibrates) have been the most successful in changing common but sub-
optimal lipoprotein patterns and group outcomes. The first of the large 
secondary prevention comparative statin/placebo treatment trials was the 
Scandinavian Simvastatin Survival Study. (4S) [50] with over 15 more 
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extending through the more recent ASTEROID [51] trial published in 2006. 
The first primary prevention comparative treatment trial was 
AFCAPS/TexCAPS [52] with multiple later comparative statin/placebo 
treatment trials including EXCEL.[53], ASCOT[54] and SPARCL.[55] [56] While 
the statin trials have all been clearly favorable for improved human 
outcomes, only ASTEROID showed evidence of atherosclerotic regression 
(slight). For both human and animal trials, those which have shown evidence 
of disease regression had all utilized more aggressive combination agent 
treatment strategies, nearly always including niacin.[35]
Diet and dietary supplements 
Vitamin B3, AKA niacin, in pharmacologic doses, (generally 1,000 to 
3,000 mg/day), sold in many OTC and prescription formulations, tends to 
improve (a) HDL levels, size and function, (b) shift LDL particle 
distribution to larger particle size and (c) lower lipoprotein(a), an 
atherosclerosis promoting genetic variant of LDL.  
Caldwell B Esselstyn Jr. MD has had an article published in 
Preventive Cardiology 2001; 4: 171-177 in which he has published 
angiograms showing regression of atherosclerosis brought about by a very 
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low fat vegan diet in some cases with cholesterol lowering medications.[57]
Dietary supplements of Omega-3 oils, especially those from the 
muscle of some deep salt water living fish species, also have clinical 
evidence of significant protective effects as confirmed by 6 double 
blind placebo controlled human clinical trials[citation needed]. 
In animals Vitamin C deficiency has been confirmed as an important 
role in development of hypercholesterolemia and atherosclerosis, but due to 
ethical reasons placebo-controlled human studies are impossible to 
do.[58] Vitamin C acts as an antioxidant in vessels and inhibits inflammatory 
process.[59] It has therapeutic properties on high blood pressure and its 
fluctuation,[60][61] and arterial stiffness in diabetes.[62] Vitamin C is also a 
natural regulator of cholesterol[63] and higher doses (over 150mg/kg daily) 
may confer significant protection against atherosclerosis even in the 
situation of elevated cholesterol levels.[64][65]
The scale of vitamin C benefits on cardiovascular system led several 
authors to the theory, that vitamin C deficiency is the primary cause of 
cardiovascular diseases.[66] The theory was unified by twice Nobel prize 
winner Linus Pauling and Matthias Rath. They discuss several metabolic and 
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genetic predispositions and their pathomechanism.[67]
Trials on Vitamin E have been done, but they have failed to find a 
beneficial effect, for various reasons, but for some patients at high risk for 
atherosclerosis there may be some benefits.[68]
Menaquinone (Vitamin K2), but not phylloquinone (Vitamin K1), 
intake is associated with reduced risk of CHD mortality, all-
cause mortality and severe aortic calcification.[69][70][71]
It has been suggested that excess iron may be involved in 
development of atherosclerosis[72][73], but one study found reducing body 
iron stores in patients with symptomatic peripheral artery 
disease through phlebotomy did not significantly decrease all-cause 
mortality or death plus nonfatal myocardial infarction and stroke.[74] Further 
studies may be warranted. 
Surgical intervention 
Other physical treatments, helpful in the short term, include minimally 
invasive angioplasty procedures that may include stents to physically expand 
narrowed arteries[75] and major invasive surgery, such as bypass surgery, to 
 
46
create additional blood supply connections that go around the more severely 
narrowed areas. 
Prophylaxis 
Patients at risk for atherosclerosis-related diseases are increasingly 
being treated prophylactically with low-dose aspirin and a statin. The high 
incidence of cardiovascular disease led Wald and Law[76] to propose 
a Polypill, a once-daily pill containing these two types of drugs in addition 
to an ACE inhibitor, diuretic, beta blocker, and folic acid. They maintain 
that high uptake by the general population by such a Polypill would reduce 
cardiovascular mortality by 80%. It must be emphasized however that this is 
purely theoretical, as the Polypill has never been tested in a clinical trial. 
Because many blood thinners, particularly salicylates such as warfarin 
and aspirin thin the blood by interfering with Vitamin K, there is recent 
evidence that blood thinners which work by this mechanism can actually 
worsen arterial calcification in the long term even though they thin the blood 
in the short term.[77][78] [27][28]
Recent research 
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An indication of the role of HDL on atherosclerosis has been with the 
rare Apo-A1 Milano human genetic variant of this HDL protein. Methods to 
increase high-density lipoprotein (HDL) particle concentrations, which in 
some animal studies largely reverses and remove atheromas, are being 
developed and researched. 
Niacin has HDL raising effects (by 10 - 30%) and showed clinical 
trial benefit in the Coronary Drug Project.However, increasing HDL by any 
means is not necessarily helpful. For example, the drug torcetrapib is the 
most effective agent currently known for raising HDL (by up to 60%). 
However, in clinical trials it also raised deaths by 60%. All studies regarding 
this drug were halted in December 2006.[79]The ERASE trial is a newer trial 
of an HDL booster which has shown promise.[80]
 The actions of macrophages drive atherosclerotic plaque 
progression. Immunomodulation of atherosclerosis is the term for 
techniques which modulate immune system function in order to 
suppress this macrophage action.[81]. 
Some controversial research has suggested a link between 
atherosclerosis and the presence of several different nanobacteria in the 
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arteries, e.g.,Chlamydophila pneumoniae, though trials of current antibiotic 
treatments known to be usually effective in suppressing growth or killing 
these bacteria have not been successful in improving outcomes.[82]
CORONARY ARTERIAL DISEASE:
 
Micrograph of a coronary artery with the most common form of coronary artery disease 
(atherosclerosis) and marked luminal narrowing. Masson's trichrome. 
Coronary artery disease (CAD)(or atherosclerotic heart disease) is the end 
result of the accumulation of atheromatous plaques within the walls of 
the coronary arteries[83] that supply the myocardium (the muscle of the heart) 
with oxygen and nutrients. It is sometimes also called coronary heart 
disease (CHD), but although CAD is the most common cause of CHD, it is 
not the only cause. 
CAD is the leading cause of death worldwide.[84] While the symptoms and 
signs of coronary artery disease are noted in the advanced state of disease, 
most individuals with coronary artery disease show no evidence of disease 
for decades as the disease progresses before the first onset of symptoms, 
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often a "sudden" heart attack, finally arises. After decades of progression, 
some of these atheromatous plaques may rupture and (along with the 
activation of the blood clotting system) start limiting blood flow to the heart 
muscle. The disease is the most common cause of sudden death[85], and is 
also the most common reason for death of men and women over 20 years of 
age[86]. According to present trends in the United States, half of healthy 40-
year-old males will develop CAD in the future, and one in three healthy 40-
year-old women.[87] .
CAD is associated with smoking, diabetes, and hypertension. A family 
history of early CAD is one of the less important predictors of CAD. Most of 
the familial association of coronary artery disease are related to common 
dietary habits. Screening for CAD includes evaluating high-density and low-
density lipoprotein (cholesterol) levels and triglyceride levels. Despite much 
press, most of the alternative risk factors including homocysteine, C-reactive 
protein (CRP), Lipoprotein (a), coronary calcium and more sophisticated 
lipid analysis have added little if any additional value to the conventional 
risk factors of smoking, diabetes and hypertension. 
However, there is a term in medicine called “Cardiac Syndrome X”, which 
describes chest pain (Angina pectoris) and chest discomfort in people who 
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do not show signs of blockages in the larger coronary arteries of their hearts 
when an angiogram (coronary angiogram) is being performed[88]. 
No one knows exactly what causes “Cardiac Syndrome X” and it is unlikely 
to have a single cause. Today, we speculate that the major contributing 
factor to “Cardiac Syndrome X” is “microvascular dysfunction”. The term 
“microvascular” refers to very small blood vessels and, in this case, very 
small arteries (arterioles, capillaries) of the heart.  
The large majority of women have the garden variety of coronary artery 
disease. Rarely, women with “Cardiac Syndrome X” have typical anginal 
syndromes that are not associated with the presence of atherosclerotic 
plaques; that is, the localized blockages are absent. Scientists speculate that 
the blood vessels in these women are diffuse abnormal. Some have falsely 
claim that the entire lining of the artery becomes thickened throughout, 
making the plaques flush with the wall of the artery without any scientific 
proof. On cardiac catheterization their coronary arteries appear smooth-
walled and normal, though they may look "small" in diameter. By the way: 
in general, female coronary arteries (like all arteries) are somewhat smaller 
than in males. 
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It is not completely clear why women are more likely than men to suffer 
from "Syndrome X"; however, hormones and other risk factors unique to 
women may play a role[89]. 
Risk factors
The following are confirmed independent risk factors for the development of 
CAD: 
1. Hypercholesterolemia (specifically, serum LDL concentrations) 
2. Smoking 
3. Hypertension (high systolic pressure seems to be most significant in 
this regard) 
4. Hyperglycemia (due to diabetes mellitus or otherwise) 
5. Type A Behavioural Patterns, TABP. Added in 1981 as an 
independent risk factor after a majority of research into the field 
discovered that TABP's were twice as likely to exhibit CAD than any 
other personality type.[ ]citation needed  
6. Hemostatic Factors[92]: High levels of fibrinogen and coagulation 
factor VII are associated with an increased risk of CAD. Factor VII 
levels are higher in individuals with a high intake of dietary fat. 
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Decreased fibrinolytic activity has been reported in patients with 
coronary atherosclerosis. 
7. Hereditary differences in such diverse aspects as lipoprotein structure 
and that of their associated receptors, homocysteine 
processing/metabolism, etc. 
8. High levels of Lp(a):[ ]citation needed  
Significant, but indirect risk factors include: 
 Lack of exercise, Stress , Diet rich in saturated fats, Diet low 
in antioxidants ,Obesity, Men over 60, Women over 65[93] 
Risk factors can be classified as 
1. Fixed: age, sex, family history 
2. Modifiable: smoking, hypertension, diabetes mellitus, obesity, etc. 
Prevention
Coronary artery disease is the most common form of heart disease in the 
Western world. Prevention centers on the modifiable risk factors, which 
include decreasing cholesterol levels, addressing obesity and hypertension, 
avoiding a sedentary lifestyle, making healthy dietary choices, and stopping 
smoking. There is some evidence that 
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lowering homocysteine levels may contribute to more heart attacks 
(NORVIT trial). The World Health Organization (WHO) recommends "low 
to moderate alcohol intake" to reduce risk of coronary artery disease 
although this remains without scientific cause and effect proof.[94]
An increasingly growing number of other physiological markers 
and homeostatic mechanisms are currently under scientific investigation. 
Patients with CAD and those trying to prevent CAD are advised to avoid fats 
that are readily oxidized (e.g., saturated fats and trans-fats), limit 
carbohydrates and processed sugars to reduce production of Low density 
lipoproteins,triacylglycerol and apolipoprotein-B. [95] [96] [97] [98] [99] It is also 
important to keep blood pressure normal, exercise and stop smoking.  
Menaquinone (Vitamin K2), but not phylloquinone (Vitamin K1), intake is 
associated with reduced risk of CAD mortality, all-cause mortality and 
severe aortic calcification.100][101][102]
Therapy - Principles of Treatment
Therapeutic options for coronary artery disease today are based on three 
principles: 
 1. Medical treatment - drugs (e.g. cholesterol lowering medications, 
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beta-blockers, nitroglycerin, calcium antagonists, etc.); 
 2. Coronary interventions as angioplasty and coronary stent-
implantation; 
 3. Coronary artery bypass grafting (CABG - coronary artery bypass 
surgery). 
Recent research efforts focus on new angiogenic treatment modalities 
(angiogenesis) and various (adult) stem cell therapies. 
A 2006 study by the Cleveland Clinic found a region on Chromosome 17 
was confined to families with multiple cases of myocardial infarction. 
Since the 1990s the search for new treatment options for coronary artery 
disease patients, particularly for so called "no-option" coronary patients, 
focused on usage of angiogenesis[46] and (adult) stem cell therapies. 
Numerous clinical trials were performed, either 
applying protein (angiogenic growth factor) therapies, such as FGF-
1 or VEGF, or cell therapies using different kinds of adult stem 
cell populations. Research is still going on - with first promising results 
particularly for FGF-1[47][48] and utilization of endothelial progenitor cells. 
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SCREENING TESTS: 
 Various screening tests are available to detect CAD, ranging from 
simple biochemical tests to complex radiological scoring systems. Each of 
the test has its own advantages and limitations. One such test is ABPI 
evaluation, which can effectively screen patients for CAD, easily and cost 
effectively.   
 
 
 
 
 
  
 
 
 
Materials and 
Methods
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MATERIALS AND METHODS: 
DURATION: MARCH 2009 to NOVEMBER 2009. 
METHOD: 
ABPI was compared between 100 patients with clinical cardiovascular 
disease versus 100 controls taken from patients attending Coimbatore 
medical college and general population of Coimbatore respectively. ABPI 
<0.9 was taken as cut off, as it has a sensitivity of 90% in detecting 
peripheral vascular disease, which may also reflect similar pathology in 
other vascular bed, like coronary arteries. Prevalence of APBI less than 0.9 
was compared and analysed between the two study populations. 
                                         The ABPI was measured according to a standard 
protocol. Vascular lower limb examination was done, by feeling the foot 
pulses (dorsalispedis and posterior tibial arteries), and identifying the best 
palpable one. ABPI was measured, by using the sphygmomanometer and a 
sonic aid hand-held Doppler probe (GIMA Ultrasound Technology Ltd, 
UK), utilizing the best-identified note of foot arteries and measuring its 
index in relation to the brachial artery. The ABI measurements were 
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compared between the two groups, with special concentration on patients 
with hypertension, diabetes , hypertension, smoking, PAD etc as comorbid 
associations of atherosclerosis. 
chi-square test was used to compare percentages. A p-value of ≤ 0.05 was  
considered statistically significant. 
STUDY POPULATION: 
PATIENTS: 100(50 men and 50 women) randomly selected coronary 
arterial disease patients (as evidenced by prior medical records, recent 
biochemical, ECG, echocardiographical data etc) attending cardiac 
department of coimbatore medical college were screened for ABPI. 
CONTROLS: Age and sex matched controls, hundred in number from 
general population, who showed no symptoms or signs of coronary arterial 
disease. 
SPECIAL REMARKS: Other confounders of CAD , like hypertension. 
Diabetes, dyslipidemia ,genetic predispositions, smokers etc were not 
matched .These were taken as separate variables for statistical analysis. 
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EXCLUSION CRITERIA: 
Patients who were acutely ill or significantly morbid.  
 
 
 
discussion
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OBSERVATIONS, RESULTS AND ANALYSIS: 
RELATIONSHIP OF CORONARY ARTERIAL DISEASE TO ABPI:
   Of the 100 patients with coronary arterial disease, 34% had a 
ABPI value below 0.9. ABPI in normal range of 0.9 to 1.2 was found in 58% 
of total. Another 8% had ABPI in higher range, which is usually associated 
with calcification of the vessel, which again is a risk for  coronary arterial 
disease. 
34
58
8
Low ABPI < 0.9
Mid Range ABPI
Between 0.9 & 1.2
High ABPI > 1.2
 
FIGURE 1 : ABPI vs. CAD 
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The people in the control group had significantly lesser numbers 
falling in the abnormal range.77% percentage of people had ABPI in the 
normal range. Only 11% of people had ABPI in the range of ischaemic limb, 
i.e. below 0.9. Though 12 % had a higher ABPI value, it should be because 
of the prevalence of higher age  and the comorbid conditions in the group. 
ABPI RANGE IN NON CAD 
12
77
11
Low ABPI < 0.9
Mid Range ABPI Between 0.9 &
1.2
High ABPI > 1.2
 
FIGURE 2 : ABPI vs. non CAD 
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FIGURE 3 : ABPI in CAD vs. non CAD. 
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Figure 3 shows the comparison of low ABPI in CAD vs. non CAD group. 
There is a significant increase of low ABPI in CAD group. It was found that, 
in students chi square the value was statistically significant. The correlation 
coefficient was 0.239 and pearsons coefficient was 0.239. This further 
confirms that the null hypothesis (there is significant difference between 
ABPI levels  in CAD and nonCAD groups) is true. 
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EFFECT OF AGE ON ABPI
The effect of age on ABPI in both groups was studied. With higher  age, 
more  numbers were seen in the abnormal ABPI range .The trend line was 
plotted. It was seen that, in the coronary arterial disease patients, people with 
lower age had abnormal ABPI readings compared to the normal patients . 
FIGURE 4 a : Age vs. ABPI (Control group) 
ABPI Vs Age Control Group (the trend 
line value is significantly above 1.1)
Trend line formula 
y = -0.001x + 1.186
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FIGURE 4 b: Age vs. ABPI (CAD Group) 
ABPI Vs Age CAD +ve Group (Trend line 
significantly lower than control group)
Trend line formula 
y = -0.000x + 1.037
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ANALYSIS OF OTHER COMORBID CONDITIONS IN THE STUDY 
RELATION OF HYPERTENSION WITH THE STUDY GROUPS 
80 people in the CAD group had hypertension, as compared to 44 in 
non CAD group (Figure 5a). The prevalence of low ABPI in CAD group 
was increased when compared to non CAD group.33.75% in  hypertensive 
CAD group had low ABPI as compared to  15.90% in the hypertensive non 
CAD group. 
Lowest prevalence was in the nonhypertensive, non CAD group, 
where the incidence was just 7%. 
The highest prevalence was noted in the hypertensive CAD group, 
where it formed 33.75% of the group, as seen in figure 5b. 
 
 
 
FIGURE 5a:  Hypertensive Chart in real numbers. 
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FIGURE 5b: Graph plotted in percentage prevalence of ABPI range in 
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group
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EFFECT OF DIABETES ABPI IN THE STUDY GROUP:
In the CAD group, 40% had diabetes. 
In the non CAD group, 38% had diabetes. 
Highest prevalence of low ABPI was found in CAD with diabetes, 
constituting 40%.(Figure 7) of 60(figure 6b) .Lowest prevalence of low 
ABPI was found in people without both diabetes or CAD, constituting 11%. 
(Figure 7) of  62 (figure 6a).  
Figure 6a: ABPI in non-CAD as related to diabetic status 
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Figure 6b: ABPI in CAD patients related to diabetic status 
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Figure7: ABPI in relation to CAD and DM in percentage. 
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EFFECT OF DYSLIPIDEMIA ON ABPI: 
Prevalence of low ABPI in dyslipidemic individuals was  in both groups was 
plotted. 
46 of CAD group and 57 of the non CAD group had dyslipidemia.(figure 8a) 
 Of  the dyslipidemics,33% of the CAD group and 35% of the non CAD 
group had low ABPI. 
Only 11% had low ABPI in the people with did not have both dyslipidemia 
and CAD. 
FIGURE 8a: ABPI in CAD related to Dyslipidemia
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FIGURE 8b: Composite analysis in Dyslipidemia 
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CONCLUSIONS 
• There is a definite increase in prevalence of low APBI in patients with 
coronary arterial disease in this study. 
• The study can be conclude by the remark that low ABPI is an 
individual risk factor for CAD, due to its increased prevalence in 
CAD group. 
• Increasing age has a lowering effect on ABPI, both in normal as well 
as patients with coronary arterial disease. 
• Diabetes has significant impact on ABPI in patients with CAD as 
observed in the study .It can be concluded that a diabetic has definite 
risk of lowering ABPI as a isolated factor , which needs future study. 
• Hypertension and Dyslipidemia were also found to increase the 
prevalence of low ABPI in coronary arterial disease patients. 
Dyslipidemia has definite role in CAD patient and low ABPI is an 
index which has been observed. 
• I conclude, as an early observation, which is only a beginning and 
more to come in future as far as this study is considered. 
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ANEXURE 1 : MASTER CHART 
Name Age Sex ABPI CAD DM Smoker Dyslipidaemia Hypertension 
Sundari 32 F 0.88 Y Y N N N 
Rosi 33 F 1.2 N N N N N 
Vennila 34 F 0.98 Y Y N Y  N 
Manoranjitham 34 F 1.1 N N N N N 
Stella 35 F 1 Y N N N Y 
Sobika 35 F 1.06 N N N Y N 
Kasthuri 36 F 1.04 Y N N Y N 
Kavitha 36 F 1.1 N N N N N 
Singari 37 F 0.9 Y N N Y Y 
Banumathi 38 F 1.16 N Y N N N 
Umarani 38 F 1.5 Y Y N N N 
Baby 39 F 1 N Y N Y N 
Jaya 39 F 0.96 Y Y N N N 
Kannamal 39 F 0.98 N N N N N 
Dhanabakium 41 F 0.92 Y Y N N Y 
Selvi 42 F 1.14 N Y N Y N 
Sangari 42 F 1.2 Y Y N Y Y 
Savithri 42 F 1 N Y N N N 
Jayalakshmi 43 F 1.08 Y Y N N Y 
Sumathi 43 F 1.2 N N N Y Y 
Karunambika 43 F 0.8 Y Y N N N 
Kalaivani 44 F 1.16 N N N Y Y 
Rani 44 F 0.94 Y Y N Y Y 
Mahalakshmi 44 F 1.14 N N N N N 
Rathinamani 44 F 1.2 Y Y N N N 
Susanmary 45 F 0.98 N N N Y N 
Ponnamal 45 F 0.74 Y Y N Y Y 
Rathna 45 F 1 N N N Y Y 
Gomathy 45 F 1.2 Y Y N N Y 
Hema 46 F 1.2 N N N Y Y 
Sangeetha 46 F 1.02 Y Y N N N 
Kaladevi 46 F 1.24 N N N N Y 
Kamalam 46 F 0.96 Y Y N Y   Y 
Rajakumari 47 F 1.34 N Y N N N 
Sarala 49 F 0.82 Y Y N N Y 
Jayanthi 50 F 1.18 N N N N Y 
Saroja 50 F 0.92 Y N N N Y 
Pichaimmalshanmugam 51 F 1.1 N N N N N 
Indrani 51 F 1.06 Y Y N Y Y 
Muthumari 51 F 1.18 N Y N Y N 
Ilavarasi 52 F 1.08 Y N N N Y 
Kanimoli 52 F 1.24 N N N N Y 
Sowdesvari 52 F 0.98 Y Y N Y Y 
Chandra 53 F 1.18 N N N N N 
Bagyalakshmi 54 F 1.14 Y Y N N Y 
Sarasvathy 54 F 1.22 N Y N N N 
Padmini 54 F 0.94 Y Y N Y Y 
Chellama 56 F 1.2 N Y N Y N 
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Veni 56 F 0.7 Y Y N Y Y 
Parameshwari 56 F 0.8 N N N Y Y 
Thangam 57 F 0.8 Y Y N N Y 
Petchiathal 57 F 1.24 N Y N N N 
Krishnaveni 57 F 1 Y Y N Y Y 
Vimala 57 F 1.1 N N N Y Y 
Maheswari 57 F 0.94 Y N N Y Y 
Mary 57 F 1.14 N N N Y N 
Janaki 57 F 1.1 Y N N Y Y 
Kalyani 58 F 1 N N N Y Y 
Valliyammal 58 F 1.22 Y N N N N 
Chellakannu 59 F 1.18 N N N N Y 
Rukmani 59 F 1.14 Y Y N Y Y 
Papathi 59 F 1.16 N Y N N N 
Marudhal 61 F 0.78 Y Y N N N 
Philomina 62 F 1.2 N Y N N N 
Arukkani 62 F 0.84 Y Y N Y Y 
Rajammal 62 F 1 N Y N Y N 
Devi 65 F 1.18 Y N N Y Y 
Vadivambal 65 F 1.2 N N N Y Y 
Karuppaye 65 F 0.72 Y Y N Y Y 
Subbathal 65 F 1.o8 N N N Y Y 
Padmavathy 66 F 1 Y Y N Y Y 
Thogaimayil 67 F 1.2 N Y N Y N 
Rajammal 67 F 0.88 Y Y N Y Y 
Venmani 68 F 0.94 N N N Y Y 
Thusimani 69 F 0.94 Y Y N Y N 
Vijaya 69 F 0.82 N N N Y Y 
Ponnuthai 71 F 0.84 Y Y N Y Y 
Maragadham 71 F 1.1 N N N Y Y 
Savithri 72 F 0.94 Y Y N N Y 
Muniammal 73 F 1.2 N N N Y Y 
Venkatalakshmi 74 F 1.5 Y Y N Y Y 
Periyammal 74 F 1.1 N N N Y Y 
Leela 75 F 0.68 Y Y N Y Y 
Easwari 76 F 1 N Y N N N 
Palaniammal 78 F 1 Y Y N N Y 
Subbulakmi 78 F 1.14 N Y N N N 
Jameela 80 F 1.4 Y Y N N Y 
Thangamani 80 F 1.3 N Y N Y N 
Mallamal 76 F  1.2 Y Y N Y Y 
Rakkamal 76 F 0.9 N N N Y Y 
Giriammal 34 F 1.06 Y Y N Y Y 
Kriahnammal 35 F 1.18 N N N Y Y 
Rajakumari 35 F 1.08 Y Y N Y N 
Karuppammal 36 F 1.24 N N N N Y 
Vanjithaayee 36 F 0.98 Y Y N Y Y 
Vimala 37 F 1.18 N N N N N 
Megamani 38 F 1.14 Y N N N N 
Ummaiyam 39 F 1.22 N Y N N N 
Kannatha 39 F 0.94 Y Y N N Y 
Ramaaya 39 F 1.2 N Y N Y N 
Sangareshvaran 39 M 0.7 Y N Y N N 
Surendran 39 M 0.8 N Y Y Y N 
Prabu 40 M 0.88 Y N Y Y Y 
 
94
Mani 41 M 1.2 N N Y Y N 
Marappan 41 M 0.98 Y N Y N Y 
Karthikeyan 42 M 1.1 N N Y Y N 
Saminathan 43 M 1 Y N Y N N 
Thanigachalam 43 M 1.06 N N Y N Y 
Maheshan 43 M 1.04 Y N Y N Y 
Rajeswari 43 M 1.1 N Y N N N 
Balasubramani 44 M 0.9 Y N Y N Y 
Ganesh 45 M 1.16 N N Y Y N 
Marimuthu 46 M 1.5 Y N Y Y Y 
Andhoni 46 M 1 N Y Y Y N 
Arumugam 47 M 0.96 Y N Y Y N 
Ragavendran 47 M 0.98 N N Y Y Y 
Ramkumar 47 M 0.92 Y N N Y Y 
Mayilsami 47 M 1.14 N N Y Y N 
Natesan 47 M 1.2 Y N Y Y N 
Nallaperumal 47 M 1 N N Y Y N 
Harisankar 48 M 1.08 Y N Y Y Y 
Vasu 48 M 1.2 N N Y N Y 
Mylsamy 48 M 0.8 Y N Y N Y 
Somasundaram 48 M 1.16 N N Y N N 
Kittan 49 M 0.94 Y N Y Y Y 
Manikandan 49 M 1.14 N N Y N Y 
Sennimalai 49 M 1.2 Y N N N N 
Chinnathambi 49 M 0.98 N N N N Y 
Murugaiyan 51 M 0.74 Y N Y N Y 
Kumaresan 52 M 1 N Y N N N 
Narayanan 53 M 1.2 Y N Y Y Y 
Devaraj 54 M 1.2 N N Y N Y 
Raman kutty 54 M 1.02 Y N Y N N 
Balamurugan 54 M 1.24 N Y Y Y N 
Sundaraj 54 M 0.96 Y N Y N Y 
Sengiah 54 M 1.34 N Y N N N 
Loganaathan 55 M 0.82 Y N Y N Y 
Mahalingam 55 M 1.18 N N Y N Y 
Manickam 55 M 0.92 Y N Y Y Y 
Jabeen 55 M 1.1 N N Y Y N 
Krishnasamy 55 M 1.06 Y N Y Y Y 
Lurdusamy 55 M 1.18 N N Y Y Y 
Angappan 55 M 1.08 Y N N Y Y 
Murugesan 56 M 1.24 N Y Y Y N 
Aanand 56 M 1.1 Y N Y N N 
Chokalingam 56 M 1 N N N Y Y 
Nagaraj 56 M 1.22 Y N Y N N 
Anbumani 56 M 1.18 N N N Y N 
Ammasai 56 M 1.14 Y N Y N Y 
Sivaram 57 M 1.16 N N Y N Y 
Bellaram 57 M 0.78 Y N N Y Y 
Bagyaraj 57 M 1.2 N Y Y N N 
Abdul azeed 57 M 0.84 Y N Y Y Y 
Muthukrishnan 58 M 1 N N Y Y N 
Venugopal 58 M 1.18 Y N Y Y Y 
Yesudas 58 M 1.2 N N N Y Y 
Ramasamy 59 M 0.72 Y N Y Y Y 
Jabamaalai 59 M 1.o8 N Y Y Y N 
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1.2 
Vijayan 59 M 1 Y N Y Y Y 
Thirumoorthy 59 M 1.2 N N Y N Y 
Alauddin 60 M .8 Y N N Y N 
Parthibandayalammal 60 M             1 N Y N Y N 
Gopal 60 M     1.18 Y N Y Y N 
Chinappan 60 M     0.96 N N N N Y 
Rathinasamy 61 M     0.9 Y N Y Y Y 
Rayappan 61 M     1.2 N Y Y Y N 
Raayan 62 M 0.88 Y N Y Y Y 
Chellapan 63 M 1.16 N N Y Y Y 
Purnam 64 M 0.88 Y N Y Y Y 
Periasamy 64 M 0.94 N Y Y Y N 
Dhandapani 64 M 0.94 Y N Y N Y 
Muthukaruppan 64 M 0.82 N Y Y N N 
Lakshman 65 M 0.84 Y N Y Y Y 
Pugalendhi 65 M 1.1 N Y Y Y N 
Ramajayam 66 M 0.94 Y N Y N Y 
Vellingiri 66 M 1.2 N Y Y N N 
Kalisamy 66 M 1.5 Y N Y Y Y 
Jeevan 66 M 1.1 N N Y Y Y 
Rasaiyah 66 M 0.68 Y N Y N N 
Muthu 67 M 1 N N Y N Y 
Karupsamy 67 M 0.8 Y N Y N Y 
Aruchami 67 M 1.02 N Y Y Y N 
Nataraj 67 M 1.04 Y N Y Y Y 
Anbalagan 67 M 1 N Y Y N N 
Mohandas 68 M 1.2 Y N Y N Y 
Gurusamy 68 M N N Y Y Y 
Sanmuganathan 69 M 0.66 Y N Y N Y 
Devasigamani 69 M 1.18 N Y N N N 
Perumal 72 M 1 Y N N N Y 
Ayyasamy 72 M 1.5 N N Y Y Y 
Sadaiyappan 73 M 1.5 Y N Y Y Y 
Annamalai 74 M 1.2 N N Y Y Y 
Velumani 75 M 0.8 Y N Y Y Y 
Kuppusamy 76 M 1.1 N N Y Y Y 
Arogyaraj 78 M 0.78 Y N Y Y Y 
Nanjappan 78 M 0.8 N N Y Y Y 
Desing 79 M 0.74 Y N Y N Y 
Shanthakumar 79 M   0.8 N N N Y Y 
Ummaiyam 46 M 1.16 Y N N N N 
Rangappan 46 M 1.2 N Y Y N N 
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ANEXURE 2: INFORMED CONSENT FORM 
DEPARTMENT OF GENERAL MEDICINE , COIMBATORE MEDICAL COLLEGE HOSPITAL. 
A COMPARATIVE STUDY OF RELATION OFAAI AND CARDIOVASCULAR DISEASE  
Informed consent form for prospective participants 
Principal Investigator:    Candidate, Junior Resident. 
Research Guide:  Prof. Dr  M Ramaswamy.MD  Chief, Medical Unit – IV. 
Organization:  Department of Medicine, Coimbatore Medical College Hospital. 
 
This informed consent form has two parts 
PART – I INFORMATION SHEET (to share the information about the research with you) 
PART – II CERTIFICATE OF CONSENT (for signatures if you agree to take part) 
(You will be given a copy of the full informed consent form.) 
PART – I INFORMATION SHEET 
I, Dr Candiadate, Junior resident in Dept of Medicine invite you to join as participant in my research on 
arterial disease, which is a very common problem in our country. I am going to give you information and invite you to 
be part of this research. You do not have to decide today whether or not you will participate in the research. Before you 
decide, you can talk to anyone you feel comfortable with about the research.  
 
There may be some words that you do not understand. Please ask me to stop as we go through the 
information and I will take time to explain.  If you have questions later, you can ask them of me, the study doctor or the 
staff. 
 
Arterial disease is a common disease due to narrowing of arteries and thereby decreasing blood supply to 
organs supplied. common example is heart attack. therefore it is important to recognize it early through noninvasive 
methods ,so that we can prevent  major catastrophic events. we are doing this research to find out a simple cost 
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effective way of screening for coronary arterial diseases. 
Diabetes mellitus is a disease in which the person has an abnormally elevated blood sugar levels due to 
decreased secretion of a hormone called insulin or due to resistance to its actions. This disease affects all the organ 
systems in the human body. In this study you will have to answer questions regarding your illness, undergo a physical 
examination, give blood for tests, and undergo an ultrasound scan of abdomen  
You are being selected because we are inviting all adults with cardiovascular diseases attending our 
cardiology clinic to enroll in the study.Your participation in this research is entirely voluntary. It is your choice whether 
to participate or not. Whether you choose to participate or not, all the services you receive at this clinic will continue 
and nothing will change. You may change your mind later and stop participating even if you agreed earlier. 
 
You will have to give details regarding your age, duration of disease, family history of the disease, any 
symptoms you are having at present, your past medical problems, surgeries and current medications. A doctor will 
examine you to look for any problems. Your height and weight will be recorded. All the data will be recorded in a 
proforma. Ten ml of blood will be drawn for doing various laboratory tests to know about the status of your disease. 
Any excess sample will be destroyed immediately after the laboratory tests are completed. Taking the blood sample 
will produce some pain and there may be slight redness at the site of puncture for a day or two. . You will be subjected 
to ultrasound scan of your abdomen 
 
On the first day you will be asked about your problems, a doctor will check you up. You will also have to give 
the blood. You will be taken blood pressure in both upper and lower limbs using an instrument called Doppler. You will 
be taken an electrocardiography. You will be required to undress till your waist. 
 
In total you will have to visit twice or thrice for the research purpose. By participating in this research it is 
possible that you may experience some discomfort as each of your visits will take longer than your usual bi-weekly 
follow up visits and will involve needle pricks to give blood samples. 
 
If you participate in this research you will be having a thorough check up, which may reveal some 
unidentified problems in you. We will promptly start the treatment for them. Also by participating you are providing 
valuable data that will help doctors understand this disease better and ultimately serve the patients in a better way. 
 
We will not be providing any money for participating in this research; you may incur more expense since you 
will have to visit the hospital more frequently. 
 
It is possible that if others in the community are aware that you are participating in this research, they may 
ask you questions. We will not be sharing the identity of those participating in the research with anyone. The 
information that we collect from this research project will be kept confidential. Information about you that will be 
collected during the research will not be identified by your name but by a number. Only the researchers will know what 
 
98
your number is and they will lock that information up with a lock and key. It will not be shared with or given to anyone 
except my research guide. 
 
The knowledge that we get from doing this research will be shared with you before it is made widely available 
to the public. Confidential information will not be shared. There will be small meetings in the community and these will 
be announced. After these meetings, we will publish the results in order that other interested people may learn from 
our research 
 
You do not have to take part in this research if you do not wish to do so. You may also stop participating in 
the research at any time you choose. It is your choice and all of your rights will still be respected 
 
If you have any questions you may ask them now or later, even after the study has started. If you wish to ask 
questions later, you may contact  
 
Dr.candidate        Prof .Dr. M Ramaswamy.MD. 
Junior Resident,     Chief, Medical Unit –1V, 
Dept Of Medicine,    Dept Of Medicine, 
Coimbatore Medical College Hospital  Coimbatore Medical College Hospital, 
Coimbatore – 18.     Coimbatore- 18. 
Phone – xxxxxxxxx         Phone – 9443366133. 
 
 
This proposal has been reviewed and approved by the Ethics Committee of Coimbatore Medical College 
Hospital which is a committee whose task it is to make sure that research participants are protected from harm. 
 
 
 
 
  
PART – II CERTIFICATE OF CONSENT 
 
I have been invited to participate in research on CARDIAC DISEASE. I understand that it will involve 
answering a detailed questionnaire, undergoing a thorough physical exam, ECG, giving blood samples and two or 
three follow-up visits. I have been informed that the risks are minimal and may include only slight pain and redness at 
sight of needle prick. I am aware that there may be no benefit to me personally and that I will not be compensated 
monetarily. I have been provided with the name of a researcher who can be easily contacted using the number and 
address I was given for that person. 
 
I have read the foregoing information or it has been read to me. I have had the opportunity to ask questions 
about it and any questions I have asked have been answered to my satisfaction. I consent voluntarily to participate as 
a participant in this research and understand that I have the right to withdraw from the research at anytime without in 
anyway affecting my medical care. 
 
Name of the participant:  ________________________________________________ 
 
Signature of the participant: ________________________________________________ 
 
Date:    ________________________________________________ 
     (Day/Month/Year) 
If illiterate 
A literate witness must sign (if possible, this person should be selected by the participant and must have no 
connection to the research team)I have witnessed the accurate reading of the consent form to the potential participant, 
translated to his mother tongue, and the individual has had opportunity to ask questions. I confirm that the individual 
has given consent freely. 
Name of witness:  _________________________ AND        Thumb print of participant 
Signature of witness: _________________________ 
Date:   _________________________ 
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   (Day/Month/Year) 
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I have accurately read or witnessed the accurate reading of the consent form to the potential participant, and 
the individual has had the opportunity to ask questions. I confirm that the individual has given consent freely. 
Name of the researcher:  ______________________________________ 
Signature of the researcher: ______________________________________ 
Date:    ______________________________________ 
    (Day/Month/Year) 
 
ANEXURE 3: ABBREVIATION 
ABPI: Ankle brachial pressure index 
CAD: Coronary arterial disease. 
IVUS: Intravascular ultrasonography 
PAD: peripheral arterial/vascular disease. 
LDL: Low density cholesterol 
HDL: High density cholesterol 
 
 
